Abstract:Abstract A key concept in medical science is that by comparing DNA, RNA, or proteins from healthy and diseased individuals, insight can be gained into the etiology of disease leading to better diagnostics and therapeutics. In this context, biorepositories have long played a key role by allowing the accumulation of biological fluids and tissues from large numbers of individuals for longitudinal or cross-sectional comparisons. Approaches to understanding human disease are based on the central dogma that information flow in living systems is from DNA to RNA to protein. At all levels, aberrations could indicate either the presence of disease or suggest underlying mechanisms of disease. However, historically DNA and RNA have been more useful for identifying risk of disease than the presence of disease, except in surgical specimens. Proteins in biological fluids [blood, urine, aspirates, etc.] have played a more prominent role in diagnostics. Indeed given that proteins are in essence the effectors of gene expression a long held goal has been to associate specific proteins in peripheral circulation that indicate the presence of disease, e.g. biomarkers of disease, especially early disease before the appearance of symptoms or other clinical indicators. This presentation will focus on issues associated with the use of biorepository fluids in this context. Three issues are fundamental: 1) specimen volume is limited and precious, 2) specimen processing requirements are not known a'priori, and 3) analytical targets are often not precisely defined. Limited specimen volume is an inherent problem because each blood draw represents a discrete end point. Unlike nucleic acids, proteins are subject to numerous post-translational biological modifications and to extensive, often rapid, degradation post specimen collection. These issues drive method development and validation, ultimately determining the amount and quality of data that can be obtained from biorepository specimens. Protein analytical methods will be reviewed from this perspective with emphasis on recent developments in multi-analyte systems and newer, highly sensitive methods. Citation Format: Patrick M. Sluss. New assays, old specimens: Multiplexing for plasma and urine. [abstract]. In: Proceedings of the AACR Special Conference on Post-GWAS Horizons in Molecular Epidemiology: Digging Deeper into the Environment; 2012 Nov 11-14; Hollywood, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2012;21(11 Suppl):Abstract nr IA01.

Western blotting: evolution of an old analytical method to a new quantitative tool for biomarker measurements

New developments in Western blot technology

Recommendations for Development and Validation of a Fit-For-Purpose Biomarker Assays Using Western Blotting; An-AAPS Sponsored Initiative to Harmonize Industry Practices

A critical path to producing high quality, reproducible data from quantitative western blot experiments

The development of microfluidic-based western blotting: Technical advances and future perspectives

Protein purification and analysis: next generation Western blotting techniques

Methodological considerations for improving Western blot analysis

Applications of western blot technique: From bench to bedside

Western Blotting a review: Principle, protocol and problem solving

The Design of a Quantitative Western Blot Experiment

Western Blotting Inaccuracies with Unverified Antibodies: Need for a Western Blotting Minimal Reporting Standard (WBMRS)

Improved semiquantitative Western blot technique with increased quantification range

Optimizing Western blotting immunodetection: Streamlining antibody cocktails for reduced protocol time and enhanced multiplexing applications

Validating Antibodies for Quantitative Western Blot Measurements with Microwestern Array

Titration-WB: A methodology for accurate quantitative protein determination overcoming reproducibility errors

Qualitative and quantitative evaluation of Simon™, a new CE-based automated Western blot system as applied to vaccine development

Development and Optimization of a Miniaturized Western Blot-Based Screening Platform to Identify Regulators of Post-Translational Modifications

Improving rigor and reproducibility in western blot experiments with the blotRig analysis

Abstract IA01: New assays, old specimens: Multiplexing for plasma and urine.

Ultra-High-Speed Western Blot using Immunoreaction Enhancing Technology